Invivyd Inc (IVVD)
2.40
-0.05
(-2.04%)
USD |
NASDAQ |
May 17, 16:00
2.40
0.00 (0.00%)
After-Hours: 20:00
Invivyd Research and Development Expense (Quarterly): 31.16M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 31.16M |
| December 31, 2023 | 62.26M |
| September 30, 2023 | 25.57M |
| June 30, 2023 | 43.62M |
| March 31, 2023 | 27.20M |
| December 31, 2022 | 19.92M |
| September 30, 2022 | 30.13M |
| Date | Value |
|---|---|
| June 30, 2022 | 37.13M |
| March 31, 2022 | 92.04M |
| December 31, 2021 | 68.43M |
| September 30, 2021 | 45.37M |
| June 30, 2021 | 35.07M |
| March 31, 2021 | 34.03M |
| September 30, 2020 | 7.251M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.251M
Minimum
Sep 2020
92.04M
Maximum
Mar 2022
39.94M
Average
34.55M
Median
Research and Development Expense (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 21.15M |
| Viking Therapeutics Inc | 24.10M |
| Stoke Therapeutics Inc | 22.37M |
| 180 Life Sciences Corp | -0.0364M |
| MAIA Biotechnology Inc | 3.717M |